Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carola Boccomini

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Hemasphere|May 4, 2026
Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trialFrancesca Cordero, Simone Ferrero, Simone Pernice, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trialSara Galimberti, Stefano Luminari, Elena Ciabatti, et al.
Blood Advances|April 14, 2023
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trialSimone Ferrero, Daniele Grimaldi, Elena Arrigoni, et al.
Blood Advances|January 14, 2025
Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trialSimone Ragaini, Anna Galli, Elisa Genuardi, et al.
American Journal of Hematology|May 14, 2025
Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 TrialRexhep Durmo, Stephane Chauvie, Carla Minoia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2021
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 StudyStefano Luminari, Martina Manni, Sara Galimberti, et al.
Haematologica|November 1, 2019
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trialRiccardo Bruna, Fabio Benedetti, Carola Boccomini, et al.
The New England Journal of Medicine|June 3, 2022
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Mats Jerkeman, et al.
British Journal of Haematology|May 14, 2026
Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53)Miguel Bastos-Boente, Alejandro Medina-Herrera, Almudena Navarro-Bailón, et al.
Leukemia|January 18, 2023
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II studyAnnalisa Chiappella, Anna Dodero, Andrea Evangelista, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Hemasphere|May 4, 2026
Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trialFrancesca Cordero, Simone Ferrero, Simone Pernice, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trialSara Galimberti, Stefano Luminari, Elena Ciabatti, et al.
Blood Advances|April 14, 2023
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trialSimone Ferrero, Daniele Grimaldi, Elena Arrigoni, et al.
Blood Advances|January 14, 2025
Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trialSimone Ragaini, Anna Galli, Elisa Genuardi, et al.
American Journal of Hematology|May 14, 2025
Total Metabolic Tumor Volume Is a Strong Independent Prognostic Factor in Follicular Lymphomas: Results From a Sub-Study of the FOLL12 TrialRexhep Durmo, Stephane Chauvie, Carla Minoia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2021
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 StudyStefano Luminari, Martina Manni, Sara Galimberti, et al.
Haematologica|November 1, 2019
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trialRiccardo Bruna, Fabio Benedetti, Carola Boccomini, et al.
The New England Journal of Medicine|June 3, 2022
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Mats Jerkeman, et al.
British Journal of Haematology|May 14, 2026
Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53)Miguel Bastos-Boente, Alejandro Medina-Herrera, Almudena Navarro-Bailón, et al.
Leukemia|January 18, 2023
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II studyAnnalisa Chiappella, Anna Dodero, Andrea Evangelista, et al.
Pageof 4